Search

Your search keyword '"Weinhold, Kent"' showing total 200 results

Search Constraints

Start Over You searched for: Author "Weinhold, Kent" Remove constraint Author: "Weinhold, Kent" Database Unpaywall Remove constraint Database: Unpaywall
200 results on '"Weinhold, Kent"'

Search Results

1. Differences in microenvironment of lung cancer and pleural effusions by single-cell RNA sequencing

3. Supplementary Figure 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells

4. Supplementary Figure 7 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

5. Data from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

6. Figure S1 from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma

7. Table S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

8. Figure S2 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

9. Figure S2 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

10. Table S1 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

11. Supplementary Figure 5 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

12. Supplementary Figure 3 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells

13. Figure S1 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

14. Supplementary Figure 4 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

15. Table S1 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

16. Supplementary Figure 1 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

17. Figure S1 from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma

18. Supplementary Figure 2 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

19. Table S1 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

20. Supplementary Figure 2 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells

21. Supplementary Figure 3 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells

22. Figure S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

23. Supplementary Table 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells

24. Supplementary Figure 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells

25. Figure S3 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

26. Table S3 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

27. Figure S2 from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma

28. Figure S1 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

29. Figure S1 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

30. Supplementary Figure 6 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

31. Table S3 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

32. Figure S3 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

33. Supplementary Figure 7 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

34. Supplementary Figure 4 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

35. Supplementary Table 1 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

36. Figure S2 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

37. Figure S1 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

38. Supplementary Figure 3 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

39. Supplementary Figure 6 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

40. Supplementary Table 1 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells

41. Data from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

42. Table S2 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

43. Supplementary Figure 2 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

44. Supplementary Figure 1 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

45. Table S1 from Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma

46. Supplementary Table 2 from Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells

47. Table S2 from Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab

48. Figure S2 from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma

49. Supplementary Figure 3 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

50. Supplementary Figure 5 from T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

Catalog

Books, media, physical & digital resources